Cor Vasa 2020, 62(3):267-271 | DOI: 10.33678/cor.2020.019

(Transthyretin amyloidosis)

Renáta Aiglová^a, Miloš Táborský^a, Pavla Flodrová^b, Alexander Schee^c

^a I. interní klinika - kardiologická, Lékařská fakulta Univerzity Palackého a Fakultní nemocnice Olomouc

^b Ústav klinické a molekulární patologie, Lékařská fakulta Univerzity Palackého a Fakultní nemocnice Olomouc

^c Kardiocentrum, Nemocnice v Karlových Varech

Transthyretin amyloidosis is a disease that has been considered as rare. However, recent studies have shown that this disorder is underdiagnosed. Clinical manifestation of this disease is variable, cardiac impairment can be isolated, but often manifestation of this disease is also polyneuropathy. Diagnostic and treatment have recently changed. New drugs that affect positively not only mortality, but also quality of life, have been introduced to clinical practice.

Keywords: Amyloidosis, Heart failure, Neuropathy, Transthyretin

Received: February 6, 2020; Revised: March 12, 2020; Accepted: March 20, 2020; Published: July 29, 2020  Show citation